You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Nordisk
since
auto-detected in 120 stories
11 hours ago
The partnership will enable Novo to better use AI to analyze complex datasets, and identify promising new drugs.
7 days ago
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment ⊖
CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.
12 days ago
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison ○
Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.
13 days ago
Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator ⊕
The new recommendation will significantly expand access to Wegovy on the England's NHS.
14 days ago
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly ⊕
Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as much as $600 a year on the pill.
21 days ago
Fat jabs for £10 a MONTH? Indian drug companies launch cheaper GLP-1s to rival Wegovy and Ozempic ⊕
found
a story from The Daily Mail 💩 › The Daily Mail
Novo Nordisk's exclusive hold on semaglutide - the active ingredient in popular fat-busting GLP-1 jabs such as Wegovy and Ozempic - expired last Friday.
43 days ago
Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly ○
found
Novo Nordisk is investing in a facility in Ireland as it expands its production capacities of the newly launched Wegovy pill, the Danish drugmaker said Monday.
49 days ago
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients ⊖
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs.
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades ⊖
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
50 days ago
Novo Nordisk shares drop 10% after poor weight loss trial result ⊖⊖
Once-a-week injection achieved weight loss of 23%, which is lower than some existing treatments